Vamsi Bollu

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

Eric Q. Wu, Scott J. Johnson, Nicolas Beaulieu et al. · Current Medical Research and Opinion · 2009 · 131 citations

Pharmacy, Insurance, Pharmacoeconomics +15

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

Eric Q. Wu, Annie Guérin, Andrew P. Yu et al. · Current Medical Research and Opinion · 2010 · 65 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +8

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

James Signorovitch, Eric Q. Wu, Keith A. Betts et al. · Current Medical Research and Opinion · 2011 · 54 citations

Medicine, Hematology, Pharmacology +12

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

Meaghan E. StCharles, Vamsi Bollu, Elizabeth Hornyak et al. · Blood · 2009 · 39 citations

Pharmacy, Pharmacology, Pharmacotherapy +9

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD

Vamsi Bollu, Frank R. Ernst, John Karafilidis et al. · International Journal of COPD · 2013 · 35 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17